Teva Pharmaceutical Industries Limited (TEVA) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Drug Manufacturers - Specialty & Generic
Teva Pharmaceutical Industries Limited (TEVA) Profile & Business Summary
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Key Information
| Ticker | TEVA |
|---|---|
| Exchange | NYSE |
| Official Site | https://www.tevapharm.com |
Market Trend Overview for TEVA
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-03-25 (ET)
As of 2026-03-25, TEVA is moving sideways without a clear direction. Over the longer term, the trend remains bullish.
TEVA last closed at 29.46. The price is about 0.7 ATR below its recent average price (30.02), and the market is currently in a sideways market without a clear direction. Price at 29.46 is moving between minor support near 28.38 and minor resistance near 30.30. Direction remains unclear. View Support & Resistance from Options
The market is moving sideways, with no clear direction. Both upside and downside risks remain in play.
Trend score: 35 out of 100. Overall alignment is unclear. The market is currently in a sideways market without a clear direction. The longer-term trend is still positive, but short-term signals are not yet confirming it.
There is no clear risk level acting as a key boundary right now.
On 2026-02-12, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-02-25] Price moved quickly and looked strong, but participation was limited.
Recent price action shows orderly upward progression with no major deterioration in bar-level efficiency. Structural conditions remain broadly constructive.
There was no clear sign of meaningful positions being carried into the overnight session.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is modestly below the recent estimated cost basis of 30.15, so the recent structure is still leaning somewhat under pressure. Price is in the upper half of the main cost band (28.54 to 29.69), which is usually a healthier short-term location because price is holding the stronger side of recent trading activity. The higher up selling area sits around 30.63 to 30.74, so rebounds may begin to slow as price pushes into that zone. Recent positioning looks fairly balanced, with 37% in profit and 63% under water. From a trading point of view, the main question is whether rebounds remain healthy enough to reach and absorb the higher overhead supply zone.
Short Interest & Covering Risk for TEVA
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is relatively low, indicating limited pressure from short positions. (Historical percentile: 4%)
Structure Analysis
TEVA Short positioning is starting to look crowded. Current days to cover is 5.0 trading days, meaning short positions would unwind more slowly than usual. Short covering could add extra momentum to price moves. Price is already trending lower (20D return -12.4%). The current configuration reflects active downside pressure rather than latent structural fragility.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. Average trading volume is weakening, indicating contracting liquidity. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 2× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-02-27 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.